New Enterprise Associates

New Enterprise Associates, Inc. is a private equity and venture capital firm established in 1977 and headquartered in Menlo Park, California, with additional offices in India and China. The firm specializes in investments across various stages of company development, including seed, start-up, early stage, and later stage, with a focus on sectors such as information technology, healthcare, and energy technology. NEA's investment strategy encompasses a wide range of industries, including consumer internet, software, biotechnology, medical devices, and alternative energy. With over $19 billion in cumulative committed capital, the firm has a notable track record, having participated in more than 210 portfolio company IPOs and over 360 acquisitions. NEA aims to invest between $0.05 million and $20 million, targeting both domestic and international markets, particularly in Asia and the Americas.

Michael James Barrett

Partner Emeritus

Kate Barrett

Marketing Partner

Peter J. Barris

Chairman

Ronald D. Bernal

Venture Partner

Ron Bernal

Venture Partner

Tak Cheung

Partner

Philip Chopin

Managing Director

Louis Citron

Chief Administrative Officer and Chief Legal Officer

Robert Croce

Venture Advisor

Bala Deshpande

Sr. Managing Director, India

Lexi Eisenberg

Associate

Anthony A. Florence

Managing General Partner, Technology

Tony Florence

General Partner

Carol Gallagher

Advisor

Tracy Howe

Investment Professional

Suzanne Hooper King

Partner

Liza Landsman

General Partner

Michael Li

Investor

Tiffany Luck

Partner

Joshua Makower

General Partner

Edward T. Mathers

Partner

John Nehra

Retired Special Partner

Michael D. O'Dell

Venture Partner

Santhosh Palani

Principal

Greg Papadopoulos

Venture Partner

Michele Park

Partner

Arno Allan Penzias

Venture Advisor

Eugene A. Trainor

COO

James G. Treybig

Venture Advisor

Paul Walker

General Partner

Harry Weller

Former General Partner

Past deals in Connecticut

Trevi Therapeutics

Post in 2022
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in New Haven, Connecticut, dedicated to developing and commercializing nalbuphine ER, an investigational therapy. The company's lead product, Haduvio, is an oral extended-release formulation of nalbuphine currently undergoing Phase IIb/III clinical trials. Trevi Therapeutics is focused on addressing serious neurologically mediated conditions, including chronic pruritus, chronic cough associated with idiopathic pulmonary fibrosis, and levodopa-induced dyskinesia in Parkinson's disease patients. The ongoing PRISM trial evaluates Haduvio's effectiveness in treating severe pruritus related to prurigo nodularis, highlighting its potential in managing conditions linked by a common pathophysiology involving opioid receptors in the nervous system. Founded in 2011, Trevi Therapeutics aims to provide innovative therapeutic solutions for patients with significant unmet medical needs.

Plaid

Series D in 2021
Plaid Inc. is a technology platform that enables users to connect their bank accounts to various applications, aiming to democratize financial services through innovative solutions. Founded in 2012 and based in San Francisco, Plaid provides a suite of APIs that allow developers to create financial products that connect consumers with traditional financial institutions. Its offerings include tools for accessing transaction history, authenticating bank accounts, verifying identities, and checking real-time account balances and income. These products are utilized across various sectors, including personal finance, consumer payments, lending, banking, and brokerage. Plaid serves a wide range of clients, from startups to Fortune 50 companies, facilitating the development of modern financial services and applications.

New Wave Foods

Series A in 2021
New Wave Foods, Inc. specializes in producing and selling plant-based seafood products, focusing primarily on sustainable shrimp alternatives. Founded in 2015 and headquartered in San Francisco, California, the company offers a variety of items, including sautéed, grilled, breaded, and fried shrimp, as well as shrimp tacos and salads. Its products are made from sustainably sourced seaweed and soy protein, enriched with natural flavors and essential amino acids, providing a healthy, low-calorie, and zero-cholesterol option for consumers. Targeting the culinary market in the United States, New Wave Foods aims to preserve and enrich seafood traditions through its innovative plant-based offerings.

Trevi Therapeutics

Series C in 2019
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in New Haven, Connecticut, dedicated to developing and commercializing nalbuphine ER, an investigational therapy. The company's lead product, Haduvio, is an oral extended-release formulation of nalbuphine currently undergoing Phase IIb/III clinical trials. Trevi Therapeutics is focused on addressing serious neurologically mediated conditions, including chronic pruritus, chronic cough associated with idiopathic pulmonary fibrosis, and levodopa-induced dyskinesia in Parkinson's disease patients. The ongoing PRISM trial evaluates Haduvio's effectiveness in treating severe pruritus related to prurigo nodularis, highlighting its potential in managing conditions linked by a common pathophysiology involving opioid receptors in the nervous system. Founded in 2011, Trevi Therapeutics aims to provide innovative therapeutic solutions for patients with significant unmet medical needs.

Plaid

Series C in 2018
Plaid Inc. is a technology platform that enables users to connect their bank accounts to various applications, aiming to democratize financial services through innovative solutions. Founded in 2012 and based in San Francisco, Plaid provides a suite of APIs that allow developers to create financial products that connect consumers with traditional financial institutions. Its offerings include tools for accessing transaction history, authenticating bank accounts, verifying identities, and checking real-time account balances and income. These products are utilized across various sectors, including personal finance, consumer payments, lending, banking, and brokerage. Plaid serves a wide range of clients, from startups to Fortune 50 companies, facilitating the development of modern financial services and applications.

Trevi Therapeutics

Series C in 2018
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in New Haven, Connecticut, dedicated to developing and commercializing nalbuphine ER, an investigational therapy. The company's lead product, Haduvio, is an oral extended-release formulation of nalbuphine currently undergoing Phase IIb/III clinical trials. Trevi Therapeutics is focused on addressing serious neurologically mediated conditions, including chronic pruritus, chronic cough associated with idiopathic pulmonary fibrosis, and levodopa-induced dyskinesia in Parkinson's disease patients. The ongoing PRISM trial evaluates Haduvio's effectiveness in treating severe pruritus related to prurigo nodularis, highlighting its potential in managing conditions linked by a common pathophysiology involving opioid receptors in the nervous system. Founded in 2011, Trevi Therapeutics aims to provide innovative therapeutic solutions for patients with significant unmet medical needs.

Trevi Therapeutics

Series C in 2017
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in New Haven, Connecticut, dedicated to developing and commercializing nalbuphine ER, an investigational therapy. The company's lead product, Haduvio, is an oral extended-release formulation of nalbuphine currently undergoing Phase IIb/III clinical trials. Trevi Therapeutics is focused on addressing serious neurologically mediated conditions, including chronic pruritus, chronic cough associated with idiopathic pulmonary fibrosis, and levodopa-induced dyskinesia in Parkinson's disease patients. The ongoing PRISM trial evaluates Haduvio's effectiveness in treating severe pruritus related to prurigo nodularis, highlighting its potential in managing conditions linked by a common pathophysiology involving opioid receptors in the nervous system. Founded in 2011, Trevi Therapeutics aims to provide innovative therapeutic solutions for patients with significant unmet medical needs.

Plaid

Series B in 2016
Plaid Inc. is a technology platform that enables users to connect their bank accounts to various applications, aiming to democratize financial services through innovative solutions. Founded in 2012 and based in San Francisco, Plaid provides a suite of APIs that allow developers to create financial products that connect consumers with traditional financial institutions. Its offerings include tools for accessing transaction history, authenticating bank accounts, verifying identities, and checking real-time account balances and income. These products are utilized across various sectors, including personal finance, consumer payments, lending, banking, and brokerage. Plaid serves a wide range of clients, from startups to Fortune 50 companies, facilitating the development of modern financial services and applications.

Spine Wave

Series F in 2016
Spine Wave, Inc. manufactures and markets medical equipment for the treatment of spinal disorders. It offers expandable PEEK spacers and expandable interbody devices for posterior surgery; pivoting spacer systems; lateral spacer systems, XDL expandable devices, and lateral access systems for lateral stabilization; Leva PX, an expandable interbody device for the treatment of spinal disorders; GraftMag Graft Delivery System to deliver large amounts of bone graft; and fixation products, such as spine systems for treating degeneration, deformity, tumor, and trauma of the thoracolumbar spine, as well as adjacent level systems. The company also offers anterior cervical plate systems that provide stabilization as an adjunct to spinal fusion from C2-C7 through anterior screw fixation; and cervical spacer systems to treat degenerative disc disease from C2-T1. It offers its products through distributors. Spine Wave, Inc. was founded in 2001 and is based in Shelton, Connecticut.

Plaid

Series A in 2014
Plaid Inc. is a technology platform that enables users to connect their bank accounts to various applications, aiming to democratize financial services through innovative solutions. Founded in 2012 and based in San Francisco, Plaid provides a suite of APIs that allow developers to create financial products that connect consumers with traditional financial institutions. Its offerings include tools for accessing transaction history, authenticating bank accounts, verifying identities, and checking real-time account balances and income. These products are utilized across various sectors, including personal finance, consumer payments, lending, banking, and brokerage. Plaid serves a wide range of clients, from startups to Fortune 50 companies, facilitating the development of modern financial services and applications.

Loxo Oncology

Series B in 2014
Loxo Oncology, Inc., a biopharmaceutical company, develops and sells medicines for patients with genetically defined cancers in the United States. Its lead product candidate comprises larotrectinib, an oral selective inhibitor of tropomyosin receptor kinase (TRK), which is in adult Phase 1 trial, a pediatric Phase 1/2 trial, and an adult/adolescent Phase 2 trial for the treatment of patients with tumor types, such as lung, head and neck, melanoma, colorectal, sarcoma, and breast cancer. The company’s preclinical programs include LOXO-195, a drug candidate in preclinical development to address predicted acquired resistance mechanisms; RET inhibitor that optimizes potency for rearranged during transfection (RET) fusion proteins, mutations, and anticipated mechanisms of acquired resistance; and FGFR inhibitor that enables potently inhibiting FGFR isoforms comprising four isoforms with tyrosine kinase domains. It has a drug discovery collaboration agreement with Array BioPharma, Inc.; strategic partnership agreement with Illumina, Inc.; research collaboration agreement with Veracyte, Inc.; and strategic partnership agreement with Amoy Diagnostics Co., Ltd. and PREMIA Holdings (HK) Ltd. Loxo Oncology, Inc. was founded in 2013 and is headquartered in Stamford, Connecticut. Loxo Oncology, Inc. is a subsidiary of Eli Lilly and Company.

Plaid

Seed Round in 2013
Plaid Inc. is a technology platform that enables users to connect their bank accounts to various applications, aiming to democratize financial services through innovative solutions. Founded in 2012 and based in San Francisco, Plaid provides a suite of APIs that allow developers to create financial products that connect consumers with traditional financial institutions. Its offerings include tools for accessing transaction history, authenticating bank accounts, verifying identities, and checking real-time account balances and income. These products are utilized across various sectors, including personal finance, consumer payments, lending, banking, and brokerage. Plaid serves a wide range of clients, from startups to Fortune 50 companies, facilitating the development of modern financial services and applications.

Spine Wave

Series E in 2011
Spine Wave, Inc. manufactures and markets medical equipment for the treatment of spinal disorders. It offers expandable PEEK spacers and expandable interbody devices for posterior surgery; pivoting spacer systems; lateral spacer systems, XDL expandable devices, and lateral access systems for lateral stabilization; Leva PX, an expandable interbody device for the treatment of spinal disorders; GraftMag Graft Delivery System to deliver large amounts of bone graft; and fixation products, such as spine systems for treating degeneration, deformity, tumor, and trauma of the thoracolumbar spine, as well as adjacent level systems. The company also offers anterior cervical plate systems that provide stabilization as an adjunct to spinal fusion from C2-C7 through anterior screw fixation; and cervical spacer systems to treat degenerative disc disease from C2-T1. It offers its products through distributors. Spine Wave, Inc. was founded in 2001 and is based in Shelton, Connecticut.

Spine Wave

Series D in 2007
Spine Wave, Inc. manufactures and markets medical equipment for the treatment of spinal disorders. It offers expandable PEEK spacers and expandable interbody devices for posterior surgery; pivoting spacer systems; lateral spacer systems, XDL expandable devices, and lateral access systems for lateral stabilization; Leva PX, an expandable interbody device for the treatment of spinal disorders; GraftMag Graft Delivery System to deliver large amounts of bone graft; and fixation products, such as spine systems for treating degeneration, deformity, tumor, and trauma of the thoracolumbar spine, as well as adjacent level systems. The company also offers anterior cervical plate systems that provide stabilization as an adjunct to spinal fusion from C2-C7 through anterior screw fixation; and cervical spacer systems to treat degenerative disc disease from C2-T1. It offers its products through distributors. Spine Wave, Inc. was founded in 2001 and is based in Shelton, Connecticut.

Spine Wave

Series C in 2006
Spine Wave, Inc. manufactures and markets medical equipment for the treatment of spinal disorders. It offers expandable PEEK spacers and expandable interbody devices for posterior surgery; pivoting spacer systems; lateral spacer systems, XDL expandable devices, and lateral access systems for lateral stabilization; Leva PX, an expandable interbody device for the treatment of spinal disorders; GraftMag Graft Delivery System to deliver large amounts of bone graft; and fixation products, such as spine systems for treating degeneration, deformity, tumor, and trauma of the thoracolumbar spine, as well as adjacent level systems. The company also offers anterior cervical plate systems that provide stabilization as an adjunct to spinal fusion from C2-C7 through anterior screw fixation; and cervical spacer systems to treat degenerative disc disease from C2-T1. It offers its products through distributors. Spine Wave, Inc. was founded in 2001 and is based in Shelton, Connecticut.

Mission Critical Software

Venture Round in 1997
Mission Critical Software provides systems administration and operations management software productsvfor corporate and Internet-based Windows NT networks. Their OnePoint productvsuite is designed to improve the reliability, performance and security of even the largest and most complex computing environments by simplifying andvautomating key systems management functions.

Mission Critical Software

Venture Round in 1997
Mission Critical Software provides systems administration and operations management software productsvfor corporate and Internet-based Windows NT networks. Their OnePoint productvsuite is designed to improve the reliability, performance and security of even the largest and most complex computing environments by simplifying andvautomating key systems management functions.